IBDEI15B ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20520,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,20521,0)
 ;;=V11.2^^131^1289^32
 ;;^UTILITY(U,$J,358.3,20521,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20521,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,20521,1,5,0)
 ;;=5^Hx of Dysthymia
 ;;^UTILITY(U,$J,358.3,20521,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,20522,0)
 ;;=V15.81^^131^1289^60
 ;;^UTILITY(U,$J,358.3,20522,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20522,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,20522,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,20522,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,20523,0)
 ;;=V10.43^^131^1289^44
 ;;^UTILITY(U,$J,358.3,20523,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20523,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,20523,1,5,0)
 ;;=5^Hx of Ovarian CA
 ;;^UTILITY(U,$J,358.3,20523,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,20524,0)
 ;;=V12.71^^131^1289^45
 ;;^UTILITY(U,$J,358.3,20524,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20524,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,20524,1,5,0)
 ;;=5^Hx of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,20524,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,20525,0)
 ;;=V10.46^^131^1289^48
 ;;^UTILITY(U,$J,358.3,20525,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20525,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,20525,1,5,0)
 ;;=5^Hx of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,20525,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,20526,0)
 ;;=V11.0^^131^1289^50
 ;;^UTILITY(U,$J,358.3,20526,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20526,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,20526,1,5,0)
 ;;=5^Hx of Schizophrenia
 ;;^UTILITY(U,$J,358.3,20526,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,20527,0)
 ;;=V10.83^^131^1289^51
 ;;^UTILITY(U,$J,358.3,20527,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20527,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,20527,1,5,0)
 ;;=5^Hx of Skin Cancer (Non-Melanoma)
 ;;^UTILITY(U,$J,358.3,20527,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,20528,0)
 ;;=V15.1^^131^1289^53
 ;;^UTILITY(U,$J,358.3,20528,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20528,1,4,0)
 ;;=4^V15.1
 ;;^UTILITY(U,$J,358.3,20528,1,5,0)
 ;;=5^Hx of Surgery To Heart And Great Vessels
 ;;^UTILITY(U,$J,358.3,20528,2)
 ;;=^295283
 ;;^UTILITY(U,$J,358.3,20529,0)
 ;;=V15.82^^131^1289^57
 ;;^UTILITY(U,$J,358.3,20529,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20529,1,4,0)
 ;;=4^V15.82
 ;;^UTILITY(U,$J,358.3,20529,1,5,0)
 ;;=5^Hx of Tobacco Use (not current)
 ;;^UTILITY(U,$J,358.3,20529,2)
 ;;=Hx of Tobacco Use (not current)^303405
 ;;^UTILITY(U,$J,358.3,20530,0)
 ;;=V12.01^^131^1289^54
 ;;^UTILITY(U,$J,358.3,20530,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20530,1,4,0)
 ;;=4^V12.01
 ;;^UTILITY(U,$J,358.3,20530,1,5,0)
 ;;=5^Hx of TB
 ;;^UTILITY(U,$J,358.3,20530,2)
 ;;=Hx of TB^303393
 ;;^UTILITY(U,$J,358.3,20531,0)
 ;;=V13.01^^131^1289^36
 ;;^UTILITY(U,$J,358.3,20531,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20531,1,4,0)
 ;;=4^V13.01
 ;;^UTILITY(U,$J,358.3,20531,1,5,0)
 ;;=5^Hx of Kidney Stones
 ;;^UTILITY(U,$J,358.3,20531,2)
 ;;=Hx of Kidney Stones^303403
 ;;^UTILITY(U,$J,358.3,20532,0)
 ;;=V12.51^^131^1289^59
 ;;^UTILITY(U,$J,358.3,20532,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20532,1,4,0)
 ;;=4^V12.51
 ;;^UTILITY(U,$J,358.3,20532,1,5,0)
 ;;=5^Hx of Venous Thrombosis And Embolism
 ;;^UTILITY(U,$J,358.3,20532,2)
 ;;=^303397
 ;;^UTILITY(U,$J,358.3,20533,0)
 ;;=V17.89^^131^1289^18
 ;;^UTILITY(U,$J,358.3,20533,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20533,1,4,0)
 ;;=4^V17.89
